Dec 30, 2024 · AXS-05 caused no cognitive decline as measured by the MMSE, or sedation (see press release, slides). On June 26, 2020, the U.S. Food and Drug Administration granted AXS …

AXS-05: an investigational treatment for Alzheimer's disease-associated agitation. Expert Opin Investig Drugs . 2022 Aug;31(8):773-780. Epub 2022 Jul 6 PubMed .

Iosifescu DV, Jones A, O'Gorman C, Streicher C, Feliz S, Fava M, Tabuteau H.Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: …

May 22, 2023 · Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022 Jul;179(7):490-499. Epub …

Nov 25, 2015 · Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 …

Nov 25, 2015 · Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 …

Network meta-analysis (NMA) of dextromethorphan-bupropion (AXS-05) efficacy and safety in major depressive disorder. Eur Neuropsychopharmacol. 2024 Sep;86:18-19. Epub 2024 Jun …

May 22, 2024 · Papers. Garay RP, Grossberg GT.AVP-786 for the treatment of agitation in dementia of the Alzheimer's type. Expert Opin Investig Drugs. 2017 Jan;26(1):121-132.

AXS-05 ; Paper Citations. Lundin A, Dietrichs E, Haghighi S, Göller ML, Heiberg A, Loutfi G, Widner H, Wiktorin K, Wiklund L, Svenningsson A, Sonesson C, Waters N, Waters S, Tedroff …

Nov 25, 2015 · Find a Therapeutic By Name Go AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-0805 ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 …